The U.S. will likely emerge the winner in a "cold currency war" that is heating up, an expert said.Currenciesread more
These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
Tariffs are the only instrument left for addressing China's systematic and excessive surpluses on its U.S. trades, writes Michael Ivanovitch.US Economyread more
In its latest attempt to build market credibility, China on Monday launched the Science and Technology Innovation Board, or "STAR Market," on which 25 companies were listed.China Economyread more
When Cathy Hsu and Tony Hsieh wanted to build an English language app for Chinese children, they decided to follow Facebook and Google's lead.Start-upsread more
Stocks in Asia were lower on Monday, as shares on a new Nasdaq-style technology board on the Shanghai Stock Exchange skyrocketed on their debut day.Asia Marketsread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
The firing of the tear gas was the latest confrontation between police and protesters who have taken to the streets for over a month to fight a proposed extradition bill and...China Politicsread more
Last week shows that oil prices are not the indicator for Middle East tensions they once were, and worries about global demand and growing U.S. production has changed that...Market Insiderread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Check out the companies making headlines after the bell Tuesday:
Shares of Juno Therapeutics soared in extended trading after the biopharmaceutical company announced that the FDA removed the clinical hold on a cancer drug trial. The trial, dubbed the "ROCKET" trial, focuses on adult patients with relapsed or refractory B cell acute lymphoblastic leukemia.
Sage Therapeutics climbed slightly after the drugmaker announced positive results for a phase 2 trial involving a new drug to treat postpartum depression.The company said data on 21 patients showed that the company's drug, SAGE-547, achieved a statistically significant reduction in symptoms at 60 hours, compared with a placebo, on a standard depression scale used in clinical research.
CytRx shares dropped after hours after the company's announcement on Tuesday that its cancer drug trial did not meet expectations. "This analysis did not provide for sufficient follow-up for the nearly two-thirds of patients who entered the Phase 3 study after the hold was resolved and enrollment resumed," CytRx reported.
Smaller company AAR, dipped more than 10 percent following the release of its fourth-quarter and fiscal year end 2016 results. The commercial aviation distributor reported diluted earnings of 32 cents a share on $458.2 million in sales.
Teva Pharmaceuticals edged higher after hours. The company announced that it expects second-quarter revenue of $4.9 billion to $5 billion versus previous guidance of $4.8 to $4.9 billion. It expects while non-GAAP earnings in a range of $1.19 to $1.22 per share, compared with a previous range of $1.16 to $1.20 a share.
— CNBC's Dan Mangan and Berkeley Lovelace contributed to this report.